BPC
BIB icon

Banque Pictet & Cie’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Banque Pictet & Cie’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,000
Closed -$239K – 341
2016
Q4 		$239K Buy
+6,000
New +$256K 0.01% 310

Other funds holding BIB

RIA
RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
MIAN
Mariner Independent Advisor Network Overland Park, Kansas $2.33B AUM 14.85% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TH
Timber Hill Greenwich, Connecticut $15.4M AUM 30.7% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return

Banque Pictet & Cie's BIB Position: Q1 2017 in Review

Banque Pictet & Cie sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2017, closing a stake of 6,000 shares — an estimated $239K sold.

Banque Pictet & Cie first reported a position in BIB in Q4 2016 and held it in 1 quarter. The position peaked at $239K in Q4 2016. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2017.

  • Banque Pictet & Cie reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2017 after selling out during the quarter.
  • Banque Pictet & Cie sold 6,000 ProShares Ultra NASDAQ Biotechnology shares in Q1 2017, an estimated $239K.
  • Banque Pictet & Cie first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2016 and held it in 1 quarter.
  • Banque Pictet & Cie's ProShares Ultra NASDAQ Biotechnology position peaked at $239K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2017.

Based on Banque Pictet & Cie's 13F filing for Q1 2017, filed 12 May 2017.